NGM Biopharmaceuticals Inc

Overview

NGM Biopharmaceuticals Inc (NGM Bio) operates as a clinical-stage bio pharmaceutical company. It develops pipeline of biological therapeutics for the treatment of cardio-metabolic, immuno-oncology, retinal and liver diseases, and ophthalmic diseases. The company’s pipeline products include NGM282, NGM395, NGM621, NGM313, and NGM120. Its NGM313 is an agonistic antibody of the beta-klotho pathway and development candidate for the treatment of metabolic conditions such as type 2 diabetes, obesity, and non-alcoholic steatohepatitis. NGM Bio’s NGM282 is an engineered protein variant of FGF19 for the treatment of non-alcoholic steatohepatitis and bile acid-related diseases. The company’s biologic's platform incorporates multiple technologies to generate and screen monoclonal antibodies. NGM Bio is headquartered in San Francisco, California, the US.
Key Stats
Address
333 Oyster Point Blvd, South San Francisco, California
Headquarters

United States of America

Contact

1 650 2435555

Website
www.ngmbio.com
No of Employees

210

Industry

Pharmaceuticals and Healthcare

Ticker Symbol & Exchange​

NGM [NASD]

Revenue (2020)

$87 m

-16% (2020 vs 2019)
Net Income (2020)

$-102 m

-138.3% (2020 vs 2019)
Net Profit Margin

-117 %

-183.8% (2020 vs 2019)
Market Cap *

$1,633 m

EPS *

$-1.5

  *Note: Ratios based on the share price as of 6-October-2021, in absolute numbers and US$.

Peer Comparison

Key Parameters NGM Biopharmaceuticals IncAbbVie IncAstraZeneca Plc
Key Information
Headquarters United States of America United States of America United Kingdom
Headquarter City South San Francisco North Chicago Cambridge
Headquarter State/Province California Illinois -
No. of Employees 210 48,000 76,100
Entity Type Public Public Public

Products & Services

NGM Bio is a pharmaceutical company. The key products of the company include the following:

Products
  • Pipeline NGM282:
  • Nonalcoholic Steatohepatitis
  • NGM395:
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
Key Financial Charts
Sales Growth
Operating Margin
Net Income Growth
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets

Employees

Name Position Board Since Age Biography
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2019 Contracts/Agreements In January, the company signed an agreement with Merck to license an investigational product called…
2019 Contracts/Agreements In March, the company expanded their research alliance with Merck for the discovery, development and…
2018 Stock Listings/IPO In October, the company announced its plans to raise IPO of shares for US$75 million.
2015 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2013 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2013 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
03 Jan 2019 Merck Extends Option Agreement with NGM Biopharma to License NGM313 Licensing Agreement Merck & Co Inc NGM Biopharmaceuticals Inc
09 Sep 2018 This Contract Service agreement between NGM Biopharmaceuticals Inc and Lonza Group for NGM282, in the Clinical stage Contract Service Agreement NGM Biopharmaceuticals Inc Lonza Group Ltd
04 Jan 2018 Ablexis Enters into Licensing Agreement with NGM Biopharma Licensing Agreement NGM Biopharmaceuticals Inc Ablexis LLC
28 Feb 2015 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
23 Feb 2015 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
31 Oct 2014 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit

Jobs Overview

1

Active Jobs

0

Posted

0

Closed

Job Trends

Latest Jobs

Job title Company Country
Senior Director, Financial Planning & Analysis NGM Biopharmaceuticals Inc United States
Research Associate / Sr Research Associate, Cell Line Development & Engineering NGM Biopharmaceuticals Inc United States
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar